← Oncology Approval Tracker

FDA DECISION ·

Opdivo

nivolumab · Bristol Myers Squibb

Traditional approvalTraditional conversionColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As monotherapy for adults and children age 12 years or older with metastatic MSI-high or mismatch repair-deficient colorectal cancer after progression following fluoropyrimidine, oxaliplatin, and irinotecan.

LAMPGEN ANALYSIS

Why it matters

The FDA converted the previously authorized single-agent use to traditional approval.

What research teams should watch

Track this post-chemotherapy population separately from the broader same-day nivolumab–ipilimumab approval.

PRIMARY RECORDS

Sources